Parkinson's Disease (PD) is a progressive neurodegenerative disorder affecting millions globally. Characterized by motor and non-motor symptoms, PD's etiology remains elusive, necessitating continued research and understanding.
PD's hallmark is the degeneration of dopaminergic neurons in the substantia nigra, leading to dopamine deficiency. The cardinal motor symptoms include bradykinesia, rigidity, and rest tremor. Non-motor symptoms like autonomic dysfunction, cognitive impairment, and psychiatric symptoms are increasingly recognized.
Genetics play a significant role, with several PD-related genes identified. However, environmental factors and their interaction with genetic susceptibility also contribute to PD's pathogenesis. The discovery of alpha-synuclein aggregates, termed Lewy bodies, in the brains of PD patients has opened new avenues for understanding the disease's molecular basis.
Diagnosing PD can be challenging due to its heterogeneous presentation and the absence of a definitive diagnostic test. The diagnosis is primarily clinical, based on motor symptoms and response to dopaminergic therapy. Misdiagnosis is common, emphasizing the need for biomarkers for early and accurate diagnosis.
Current therapeutic strategies aim to manage symptoms, with levodopa remaining the gold standard. However, long-term use leads to motor complications. Non-pharmacological interventions, such as physiotherapy and deep brain stimulation, are also used.
Future research focuses on understanding PD's pathogenesis, identifying biomarkers, and developing disease-modifying therapies. Potential strategies include neuroprotective treatments, targeting alpha-synuclein, and gene therapy. The gut-brain axis and the role of the microbiome in PD are emerging research areas.
PD is a complex, multifactorial disease requiring a comprehensive understanding for effective management. While current treatments provide symptomatic relief, the development of disease-modifying therapies is crucial. Continued research and collaboration will undoubtedly bring us closer to this goal.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation